Last updated: July 25, 2026
Shire Development LLC sued SpecGx LLC in the District of Delaware in 2018 over alleged infringement of patents tied to Shire’s marketed drug(s) and/or Orange Book-listed products. The case is docketed as 1:18-cv-00800 and proceeds as a patent infringement matter in federal court. However, no docket-level merits, claim construction, judgment, or settlement terms can be stated from the information provided here. Without verified filings or dispositions, a complete infringement and exclusivity risk analysis cannot be produced.
What is Shire Development LLC v. SpecGx LLC 1:18-cv-00800 about?
The case caption indicates a U.S. patent infringement action by Shire Development LLC against SpecGx LLC in federal court (1:18-cv-00800). The posture is consistent with Hatch-Waxman-style “patent infringement” litigation, but the specific asserted patents, the asserted product(s), and the infringement theory cannot be identified from the case reference alone.
What patents were asserted in 1:18-cv-00800?
A patent-by-patent summary requires:
- asserted patent numbers,
- publication/application numbers,
- claims-in-suit,
- filing bases (e.g., asserted on behalf of an Orange Book listing or for a non-Orange Book right).
Those details are not present in the provided input, so no accurate asserted-patent list can be published.
What product and Orange Book listing is the dispute tied to?
Shire’s portfolio includes multiple brands with FDA-reviewed patents. Determining which Shire product drove the dispute requires linkage to:
- FDA Orange Book listings (drug name, NDA/ANDA, active ingredient, dosage form),
- the ANDA/label carve-outs at issue,
- any “use code” or formulation patent tie-in.
No such linkage is available in the provided input.
Which court and judge handled Shire Development LLC v. SpecGx LLC?
A full litigation map needs:
- the assigned judge,
- magistrate involvement,
- venue-specific scheduling orders,
- early motion deadlines.
The case identifier (1:18-cv-00800) is insufficient by itself to produce an accurate judge/case-management timeline.
When did the litigation start and what were key procedural milestones?
A litigation timeline should include, at minimum:
- complaint filing date,
- service date,
- defendant’s answer or Rule 12 posture,
- Markman schedule,
- claim construction decision date,
- summary judgment dates,
- trial dates (if any),
- final judgment or dismissal date,
- post-judgment appeal notice (if applicable).
None of those dates are provided, so a real milestone timeline cannot be stated.
What motions were filed and how did the court rule?
A meaningful analysis depends on the motion outcomes:
- motion to dismiss (12(b)(6), lack of standing, improper venue, failure to state infringement),
- motions to compel or limit expert testimony,
- Markman rulings,
- summary judgment on non-infringement or invalidity,
- injunction posture under eBay factors and PLR/PSB rules (as applicable).
No motion records are included in the provided input; therefore, no rulings can be summarized.
How did claim construction affect infringement and validity?
A claim construction analysis should cover:
- key disputed terms,
- court’s construction for each term,
- impact on infringement elements,
- impact on anticipation/obviousness scope.
Without the court’s constructions and the patents-in-suit, no claim construction impact can be credibly analyzed.
What is the litigation posture: infringement, invalidity, or both?
Typical patent cases include assertions of:
- infringement by ANDA/ANDA-label comparison,
- invalidity by anticipation/obviousness and/or statutory invalidity defenses,
- non-infringement on claim scope or product composition.
The provided input does not identify the asserted grounds or their procedural posture, so a binary “infringement vs invalidity” summary would be speculation.
Was there a Paragraph IV certification and what was the FDA/Hatch-Waxman trigger?
For Hatch-Waxman linkage, the record should show:
- Orange Book patent(s) listed for the brand,
- the type of certification (Paragraph I, II, III, IV),
- notice letter date and contents,
- FDA approval/launch timing and any 30-month stay.
No Orange Book or certification data is provided here, so no Paragraph IV framework can be laid out.
What settlement outcomes or consent judgments were reached?
Business-impact analysis requires:
- whether a settlement was reached,
- dates,
- effective terms (license scope, covenants not to sue),
- payment or reverse payment structure (if disclosed),
- launch-date commitments,
- dismissal language and who bears costs.
No settlement terms or dismissal/judgment information is provided, so this section cannot be completed.
What is the competitive and commercial exposure for Shire from this case?
To quantify exposure, the analysis needs:
- the brand’s revenue and patient base for the relevant product,
- the accused generic launch timeframe,
- remaining exclusivity and patent life for the relevant Orange Book patents,
- whether SpecGx was a viable ANDA competitor.
No product or revenue linkage is included in the provided input, so no exposure quantification can be stated.
What generic entry risks existed for SpecGx if the case was dismissed or lost?
A generic entry risk assessment depends on:
- injunction issuance status,
- residual patent estate coverage,
- whether any non-infringement findings were entered,
- whether invalidity was found.
Without disposition details, launch risk cannot be modeled.
How strong is the Shire patent estate implicated by 1:18-cv-00800?
A “strength” view should address:
- number of patents asserted,
- whether they are formulation, method-of-use, or composition claims,
- proximity to expiration,
- obviousness/enablement vulnerabilities,
- history of prior litigation or PTAB activity.
No asserted-patent data is supplied, so strength cannot be evaluated.
How does SpecGx’s product compare with the accused claims?
To compare, the record needs:
- accused product details (dose, salt form, excipients, release profile),
- label and use instructions,
- claim elements and court constructions.
No such technical record is provided.
What regulators and filings are connected to the case?
For Hatch-Waxman, the FDA record should include:
- NDA and ANDA numbers,
- submission types (ANDA, 505(b)(2)),
- approval letter date,
- exclusivity periods and forfeiture triggers,
- REMS or pediatric exclusivity impacts.
No FDA linkage is given here.
Key Takeaways
- Shire Development LLC v. SpecGx LLC (1:18-cv-00800) is a patent litigation in federal court brought by Shire Development LLC against SpecGx LLC.
- The provided case identifier does not supply the specific asserted patents, product/ANDA linkage, procedural history, claim construction, or final disposition required for an infringement, validity, settlement, or launch-risk analysis.
- A complete litigation summary and business impact assessment cannot be produced from the information provided.
FAQs
- What patents are typically asserted in Shire Development LLC v. SpecGx LLC cases like 1:18-cv-00800?
- Does 1:18-cv-00800 involve a Paragraph IV certification, and how does that affect launch timing?
- What claim terms are usually most contested in Hatch-Waxman cases involving Shire products?
- How do settlements in Shire patent litigations typically regulate generic entry dates?
- What is the usual effect of a dismissal or injunction in Shire v. generic manufacturer patent cases?
References
- Shire Development LLC v. SpecGx LLC, No. 1:18-cv-00800 (D. Del.).
